Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIRBASKIN: Tirbanibulin for Actinic Keratosis Wellbeing
NCT05741294Phase 4Completed
- Sponsor
- Almirall
- Start
- Jan 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of tirbanibulin in actinic keratosis (AK), sponsored by Almirall. Primary endpoint: Treatment Satisfaction Questionnaire for Medication Version 9 at Day 57. Started Jan 2023; status: completed.
02
Drugs
tirbanibulin
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT05741294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05741294.